Company intelligence / Profile preview
Independent Pharmaceutica
Stockholm, Sweden
- Ownership
- Private
- Development stage
- Other
01
Overview
Independent Pharmaceutica was a Swedish biotechnology company focused on developing therapeutic vaccines for the treatment of cancer. The company's lead candidate, IP-001, was a DNA-based vaccine targeting prostate-specific antigen (PSA) for patients with prostate cancer. Utilizing its proprietary i-Vax platform, the company aimed to stimulate the immune system to recognize and destroy tumor cells. Although the company advanced its lead program into Phase 1/2 clinical trials, it eventually ceased operations and was liquidated in the early 2010s.
- Therapeutic areas
- Oncology
- Modalities
- VaccineBiologicDNA vaccine
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Independent Pharmaceutica.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Independent Pharmaceutica.